Biosimilars Advisory Service

August 2013

Biosimilars Advisory Service: Acceptance of Biosimilars Across Physician Specialties

Report Authors
Andrew Merron, Ph.D.

Introduction:

Securing a positive return on biosimilar development depends on multiple clinical and nonclinical factors. Critical to success is gaining physician confidence in biosimilar products in order to drive adoption. We conducted primary market research with 560 specialty physicians across the United States and Europe to understand their perspectives on biosimilars and their expectations for use. To fully identify nuances in physician attitude and likelihood of adoption, we surveyed six different specialties and asked questions about multiple drug classes used in specific indications. Through our market research, we also uncover the trends in physician perceptions about biosimilars over time and how physicians from different specialties and geographies vary with respect to their opinions on automatic substitution, indication extrapolation, drivers and constrainers of uptake, clinical concerns and requirements, and competition from new innovative biologics.

This report is part of the Biosimilars Advisory Service. The Biosimilars Advisory Service provides insight and analysis that is vital to successful business planning in the rapidly evolving biosimilars space. Quarterly webinars detailing major developments, analyst insight addressing key market changes, therapeutic-area-specific primary research, and forecasting modules are all included in a subscription to the Biosimilars Advisory Service. Rely on us to keep you up-to-date on the biosimilars landscape and poised to maximize opportunities for your business.

Questions Answered in This Report:

  *   Understand surveyed physicians’ current level of familiarity with biosimilars: What are the similarities and differences in physician opinions with respect to physician specialty and region? How has familiarity with biosimilars evolved over time in Europe and the United States? According to surveyed specialists, how similar are branded reference biologics to their biosimilar counterparts?

  *   Uncover physician perspectives on barriers and drivers to biosimilar use and understand how  barriers can be minimized and drivers can be maximized: What are the most significant constraints to biosimilar use and which are less important? Do they vary by country and over time? What are considered to be the greatest challenges for biosimilar manufacturers according to surveyed physicians? How do physician perceptions of drivers of biosimilar use differ by region? How can biosimilar manufacturers maximize uptake by relying on the strongest drivers? How will trust in biosimilar manufacturers influence biosimilar uptake? Which companies are perceived to be the most trustworthy biosimilar manufacturers?

  *   Understand physicians’ clinical trial data expectations for biosimilars: What level of clinical trial data will convince different specialists that biosimilars and branded biologics are comparable?

  *   Understand how physicians’ attitudes translate to expected use of biosimilars: What are physicians’ opinions on indication extrapolation and pharmacy-level substitution? How quickly do physicians expect to adopt biosimilars? How will price affect physicians’ uptake of biosimilars? To what extent will novel biologics be prescribed ahead of biosimilars based on level of improvement and price?

Scope:

Markets covered: United States and Europe.

Primary research: Online quantitative survey of 560 specialty physicians in the United States and Europe.

To qualify for participation, surveyed physicians had to meet the following criteria:

- Have worked in clinical practice for a minimum of 3 years and a maximum of 30 years.

- Spend more than 75% of their professional time in clinical practice (with allowances for academic physicians to have at least 51% of their professional time in clinical practice).

- Prescribe certain biologic drugs (depending on the specialty), including the following: TNF-alpha inhibitors, Monoclonal antibodies in oncology, Erythropoiesis-stimulating agents (ESAs), Granulocyte colony-stimulating factors (G-CSFs), Pegylated interferon-alphas, Somatropin, Insulins.

Related 2013 Reports:

- Biosimilars Advisory Service: Corporate Strategies

- Biosimilars Advisory Service: Global Pipelines, Pathways, and Key Stakeholder Perceptions

- Biosimilars Advisory Service: US and EU Payer Perspectives

- Biosimilars Advisory Service: Immunology & Infectious Disease

- Biosimilars Advisory Service: Endocrinology and Nephrology

- Biosimilars Advisory Service: Oncology

Search Published Reports


Decision Resources Group brands include: